About trasuzumab
HER2-targeted monoclonal antibody
Used for
- HER2-positive breast cancer
- HER2-positive metastatic stomach or gastroesophageal junction cancer
Usual adult dose
Given by intravenous infusion. Breast cancer: usually 8 mg/kg initially, then 6 mg/kg every 3 weeks; other schedules apply. Stomach cancer: usually 8 mg/kg initially, then 6 mg/kg every 3 weeks.
Common side effects
- Infusion reactions, fever, chills, or headache
- Diarrhea, nausea, or fatigue
- Heart muscle damage or heart failure
- Low blood cell counts, especially with chemotherapy
Important warnings
- Heart function should be checked before and during treatment.
- Infusion reactions can be severe, including breathing problems or low blood pressure.
- Can harm an unborn baby; effective contraception is needed during treatment and for 7 months afterward.
- Do not substitute with other trastuzumab products without clinical guidance.
Pregnancy
May cause fetal harm. Avoid during pregnancy unless clearly necessary; effective contraception is required during treatment and for 7 months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for 7 months after the last dose.
Interactions
- Anthracycline chemotherapy can increase heart damage, including when given after trastuzumab.
- Other cancer treatments may increase heart or blood-related side effects.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.